Albumin-based nanocarriers for cancer therapy
Cancer is one of the major health problems worldwide and suitable therapies with enhanced efficacy and reduced side effects are hence being searched. In recent years, nanocarriers are gaining tremendous attention for the delivery of various therapeutic agents (both chemotherapeutics and nucleic acid...
| Autor: | |
|---|---|
| Tipo de recurso: | tesis doctoral |
| Fecha de publicación: | 2022 |
| País: | España |
| Institución: | Universidad Complutense de Madrid (UCM) |
| Repositorio: | Docta Complutense |
| Idioma: | inglés |
| OAI Identifier: | oai:docta.ucm.es:20.500.14352/3527 |
| Acceso en línea: | https://hdl.handle.net/20.500.14352/3527 |
| Access Level: | acceso abierto |
| Palabra clave: | 616-006.04-085(043.2) Cancer chemotherapy farmacoterapia Farmacología (Medicina) Oncología 3201.01 Oncología |
| Sumario: | Cancer is one of the major health problems worldwide and suitable therapies with enhanced efficacy and reduced side effects are hence being searched. In recent years, nanocarriers are gaining tremendous attention for the delivery of various therapeutic agents (both chemotherapeutics and nucleic acids) in cancer therapy. They offer multiple advantages, including improved drug delivery, targeted accumulation due to enhanced permeability and retention (EPR) effect, controlled release, improvement of circulation half-lives, biodistribution, and efficacy of encapsulated cargos, and flexibility in administration routes.This thesis is focused on the use of albumin-based nanocarriers for cancer therapy. Albumin is a versatile protein and provides biocompatibility, tumor specificity, the possibility for surface modification, and reduces toxicity. Some of the widely investigated albumin nanocarriers include polyplexes, nanoconjugates, and nanoparticles. Despite their broad potential in oncology, many studies still need to be done regarding their safety and tumor targeting enhancement. Anyhow, the potential of albumin nanocarriers is clearly supported by the FDA and EMA approved formulation, Abraxane, which is currently used for metastatic breast cancer. Therefore, further developments based on related strategies can have a dramatic impact on cancer therapy... |
|---|